INTERLEUKIN-2-RECEPTOR BLOCKADE WITH DACLIZUMAB TO PREVENT ACUTE REJECTION IN RENAL TRANSPLANTATION

Background Monoclonal antibodies that block the high-affinity interleukin-2 receptor expressed on alloantigen-reactive T lymphocytes may cause selective immunosuppression. Daclizumab is a genetically engineered human IgG1 monoclonal antibody that binds specifically to the α chain of the interleukin-2 receptor and may thus reduce the risk of rejection after renal transplantation. Methods We administered daclizumab (1.0 mg per kilogram of body weight) or placebo intravenously before transplantation and once every other week afterward, for a total of five doses, to 260 patients receiving first cadaveric kidney grafts and immunosuppressive therapy with cyclosporine, azathioprine, and prednisone. The patients were followed at regular intervals for 12 months. The primary end point was the incidence of biopsy-confirmed acute rejection within six months after transplantation. Results Of the 126 patients given daclizumab, 28 (22 percent) had biopsy-confirmed episodes of acute rejection, as compared with 47 of the ...

[1]  M. Giral,et al.  Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. , 1990, The New England journal of medicine.

[2]  R. Morris.  Mechanisms of Action of New Immunosuppressive Drugs , 1995, Kidney international. Supplement.

[3]  D. Mould,et al.  A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation. , 1997, Transplantation.

[4]  T. Taniguchi,et al.  The IL-2 IL-2 receptor system: A current overview , 1993, Cell.

[5]  R. Clark,et al.  Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[6]  T. Waldmann,et al.  Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. , 1994, Blood.

[7]  T. Strom,et al.  Therapy with monoclonal antibody to interleukin 2 receptor spares suppressor T cells and prevents or reverses acute allograft rejection in rats. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[8]  D. Mould,et al.  Determination of humanized anti-Tac in human serum by a sandwich enzyme linked immunosorbent assay. , 1995, Journal of immunological methods.

[9]  P. Familletti,et al.  Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys. , 1991, Journal of immunology.

[10]  M Levitt,et al.  A humanized antibody that binds to the interleukin 2 receptor. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[11]  R. Zietse,et al.  A DOUBLE‐BLIND, PLACEBO‐CONTROLLED STUDY OF MONOCLONAL ANTI‐INTERLEUKIN-2 RECEPTOR ANTIBODY (BT563) ADMINISTRATION TO PREVENT ACUTE REJECTION AFTER KIDNEY TRANSPLANTATION , 1995, Transplantation.

[12]  Sollinger Hw.  Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. , 1995 .

[13]  A. Matas,et al.  One-year follow-up of an open-label trial of FK506 for primary kidney transplantation. A report of the U.S. Multicenter FK506 Kidney Transplant Group. , 1996, Transplantation.

[14]  B. Kahan.  Sirolimus: a new agent for clinical renal transplantation. , 1997, Transplantation proceedings.

[15]  H. Bazin,et al.  MONOCLONAL ANTIBODIES IN PROPHYLACTIC IMMUNOSUPPRESSION AFTER LIVER TRANSPLANTATION A RANDOMIZED CONTROLLED TRIAL COMPARING OKT3 AND ANTI‐IL-2 RECEPTOR MONOCLONAL ANTIBODY LO‐TACT-1 , 1993, Transplantation.

[16]  T. Waldmann,et al.  Prolongation of primate renal allograft survival by anti-Tac, an anti-human IL-2 receptor monoclonal antibody. , 1989, Transplantation.

[17]  T. Waldmann,et al.  A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation. , 1991, Transplantation.

[18]  M. Henry,et al.  Acute rejection episodes: best predictor of long-term primary cadaveric renal transplant survival. , 1993, Transplantation proceedings.